Received Nov 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 2 | Y008483 | IM / RA |
| MENB | MENINGOCOCCAL B (TRUMENBA) | PFIZER\WYETH | 1 | HP9988 | IM / RA |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 1 | Y011020 | SC / LA |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Y011020 | OT |
Nurse reported that a pregnant patient received a dose of VARIVAX. /"26 weeks pregnant when the dose was given; No additional AE/No PQC reported.; This spontaneous prospective pregnancy report was received from a registered nurse and refers to an 18-year-old female patient. The patient had no pertinent medical history, drug reactions/allergies and concomitant therapies. On 06-Oct-2025, the pregnant patient was vaccinated with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) (lot #Y011020, expiration date: 18-Jun-2026, 1 dose totally, strength unknown), administered by subcutaneous route for immigration vaccination (Maternal exposure during pregnancy). The vaccine was reconstituted with sterile diluent (Hollister-Stier STERILE DILUENT) (lot # and expiration date were not reported). It was reported that the patient was 26 weeks pregnant when the dose was given. No additional adverse event/ No product quality complaints reported. On 07-Apr-2025, the patient became pregnant with the date of last menstrual period of 24-Mar-2025. The pregnancy due date was estimated as 12-Jan-2026. This pregnancy involved 1 fetus(es).
Sterile Diluen